Skip to content
Get BIO’s view on everything from health care to biofuels and the bioeconomy. The below articles include BIO statements, opinion, and calls to action, as well as articles and op-eds written by BIO leadership.
A bipartisan amendment to the Inflation Reduction Act (IRA), introduced in the House on January 31, would fix the law’s small molecule “pill penalty” […]
EPIC Act would fix IRA’s ‘pill penalty’ for small molecule drugs Read More »
“If you want to go fast, go alone,” said Interim Dean of UCLA’s Division of Social Sciences, Abel Valenzuela Jr., giving opening remarks at
When Medicine Stops Saving Us: The Antimicrobial Resistance Crisis Read More »
Vaccines have changed the course of human history as we know it. Since the first vaccine was discovered in the late 1700s, vaccine technology
What does the vaccine pipeline look like – and how can we strengthen it? Read More »
After the Food and Drug Administration (FDA) approved Gilead’s HIV/AIDS drug in 2001, the firm gained FDA approval for a second drug in 2015.
BIO says suit over speed of drug development is threat to innovation and new cures Read More »
The wait is finally over as the Biotechnology Innovation Organization (BIO) taps John F. Crowley, a longtime leader and tireless patient advocate in the
BIO names John F. Crowley as new President & CEO Read More »
The Biotechnology Innovation Organization (BIO) and patient advocacy organizations have seen some recent progress in their efforts to have Congress pass pharmacy benefit manager
House and Senate advance PBM legislation, advocacy groups urge passage Read More »
COVID was “a tragedy around the world,” said Rachel King, President and CEO of the Biotechnology Innovation Organization (BIO). However, COVID-19 also brought “amazing
For global health security, we need public-private partnership Read More »
Pharmacy benefit managers, or PBMs, have been in the political hot seat for a couple of years now—and for good reason. “Every day PBMs
As PBM reform maintains steam, biotech companies and patients are urged to take action Read More »
As weakening investment plagues small, innovative biotechs on both sides of the Atlantic, one bright spot in providing funding is acquisitions—though even that vital
M&A activity a bright spot in funding for biotech, expert tells 2023 BIO-Europe Read More »
Remarks from Dr. Ted W. Love, Chairman of the Biotechnology Innovation Organization (BIO) and former President and CEO of Global Blood Therapeutics, as prepared
Dr. Ted W. Love: How to reframe the narrative about biotech – and put patients first Read More »
